When a sponsor chooses a first-in-human (FIH) site, the scientific story and the facility tour matter far less than most site presentations assume.
November 6, 2026
7
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
The brochure is not the shortlist
Most FIH pitches lead with science, equipment, and square footage. Sponsors listen, then ask different questions in private. Who reviews safety data before the next cohort is dosed? Who can pause escalation? How long does it take to get a complete view of the first participants?
In an FIH study, the first cohorts carry the highest uncertainty in the program: the product has never been given to a human being before, or never by this route, at this dose, or in this population. The sponsor is buying judgment, and the first dose-escalation decision is where it becomes visible.
1. Safety governance a sponsor can actually read
The first thing a sponsor weighs is whether safety governance is real, named, and documented, not implied. That starts with a clear safety review committee (SRC), or an equivalent body defined in the protocol and in the site's standard operating procedure (SOP) set. Who sits on it? What data must it review, what quorum is required, and what happens when members disagree? If a data safety monitoring board (DSMB) is also involved, how do the two bodies interact?
Good governance is specific. It names the principal investigator (PI) as medically responsible and the sponsor's medical monitor. It states how an institutional review board (IRB) and, where applicable, an ethics committee (EC) are notified of reportable findings. It defines a decision: proceed as planned, proceed lower, expand or repeat a cohort, or stop escalation.
A sponsor cannot escalate on "safety is our top priority." A sponsor can escalate on a documented review, signed off by accountable people, based on a defined data set. Site leaders should hand over this structure in one page: members, roles, trigger, required data, and decision options.
2. Who can make the dose-escalation call, and how fast
Speed matters, but only disciplined speed. Sponsors want the shortest defensible interval between the last required safety observation in one cohort and a documented decision on the next.
That interval depends on people, not intentions. Who can make the call if the PI is unavailable? Can a qualified sub-investigator act as alternate, so a decision does not wait for one person's calendar? How is the decision recorded, so dosing never begins on a verbal understanding alone?
A credible site can describe its timeline hour by hour. Data are cut at a defined point. Laboratory results, vital signs, electrocardiogram (ECG) readings, and adverse event (AE) records are reconciled. The SRC reviews one complete package, and the decision is filed before the next cohort is scheduled. A sponsor will trade a few days for a defensible decision; it will not accept speed bought by a thin review.
3. Medical coverage when the first cohort is dosed
Sponsors probe medical coverage hard. Who is physically present during dosing and the highest-risk observation window? What resuscitation and emergency transfer arrangements are in place, and what happens if a participant deteriorates after hours? Sponsors want named coverage, not a department, the covering physician's qualifications, the nursing team's training in recognizing an AE, and how quickly a serious adverse event (SAE) reaches the PI and the sponsor.
Honesty protects a site here. Every site has limits: procedures it does not perform, populations it should not enroll, observation needs it cannot support. A site that states its limits early is more credible than one that accepts every protocol and qualifies its answers later. At Amavita Research Services, our focus is cardiovascular research, supported by 18,000 or more active cardiology patients and zero Food and Drug Administration (FDA) Form 483 findings. A defined focus is a stronger FIH argument than a claim to do everything.
4. Real-time safety data, not end-of-week summaries
Nothing undermines sponsor confidence faster than safety data that have to be reconstructed. By the escalation review, the sponsor expects one coherent record for each participant: dosing details, pharmacokinetic (PK) sampling times, laboratory values, vital sign trends, ECG results, concomitant medications, and every AE with onset, severity, relatedness, action taken, and outcome. If that record lives across paper notes, spreadsheets, and an electronic data capture (EDC) system updated days later, the review will stall, and it should.
Sponsors therefore ask how soon data are entered, who checks them, and how the site prevents a late-entered AE from changing the picture after a decision. Treat data timeliness as a safety function, not an administrative one: a data delay is a delay in deciding whether the next participant should receive a higher dose.
5. Stopping-rule discipline
Protocols define stopping rules for a reason, and sponsors watch for sites that treat them as guidance rather than boundaries. A rule may be triggered by a single SAE, a pattern of related AEs in a cohort, or laboratory thresholds named in advance. The site's job is not to negotiate with the rule in the moment. It is to recognize the trigger, pause as the protocol and its SOP set require, notify the sponsor and the IRB or EC, and document what was done and when.
Discipline here is cultural as well as procedural. A mature FIH team escalates early, describes findings plainly, and knows a well-handled pause builds more trust than a cohort pushed through on optimism. Sponsors notice whether a site asks thoughtful questions about stopping rules and sentinel dosing during feasibility.
6. Team experience that shows up under pressure
Experience matters, but sponsors look for a specific kind: evidence that this team has handled sentinel dosing, intensive sampling schedules, extended observation, rapid laboratory turnaround, and safety findings that required a difficult conversation, rather than a long list of studies in unrelated areas.
Continuity matters as much as credentials. If the team presented at feasibility is not the team that will dose the first cohort, the sponsor will discount the presentation. Who is the lead coordinator, who backs that person up, and what protocol-specific training is documented before screening begins?
A practical shortlist checklist for sponsors
Before awarding the first cohorts, a sponsor should be able to answer yes to each of these, from documents rather than conversation alone:
- Governance: A named SRC or equivalent body, with defined membership, quorum, and decision options?
- Authority: Written down who can approve, modify, or stop escalation, and who acts in their absence?
- Timeline: An hour-by-hour path from last safety observation to documented decision?
- Coverage: Named physician coverage for dosing and the full observation window, with clear emergency and transfer arrangements?
- Data: Laboratory results, vital signs, ECG readings, PK times, and AE records reaching review as one reconciled, real-time package?
- Stopping rules: Treated as hard boundaries, with a defined notification route to the sponsor, the IRB, and the EC?
- Experience: This specific team, not only this institution, has run early-phase cohorts with intensive observation?
- Limits: The site has stated clearly what it will not do and whom it will not enroll?
- Documentation: The decision, rationale, and sign-off filed before the next cohort is dosed?
A site that answers nine of nine with evidence is one a sponsor can defend when leadership asks why it should dose first.
What site leaders should fix first
If you lead a site and want more FIH work, start where sponsors decide. Write the one-page governance summary. Name your decision-makers and alternates. Measure your data-entry timing and fix the slowest step. Rehearse a stopping-rule scenario.
Those changes are unglamorous, but they answer the sponsor's real question: when the first cohort has been dosed and data are worrying, will this site make the right decision, at the right speed, with a record that proves it?
Sites that answer with evidence earn the first cohorts. At bioaccess, working anywhere from Canada down to Argentina, that is the standard we apply to ourselves first.
Julio G. Martinez-Clark is chief executive officer (CEO) of bioaccess\u00AE, a first-in-human contract research organization running early-phase trials anywhere from Canada down to Argentina, and of Amavita Research Services, a Miami cardiovascular research site he has operated for seven years with zero United States Food and Drug Administration (FDA) Form 483 inspection findings. He founded Global Trial Accelerators\u2122, a podcast for medtech and biotech founders navigating first-in-human studies.